(Q37891982)

24 August 2017

1 reference

title

Combination therapy with naltrexone and bupropion for obesity (English)

1 reference

24 August 2017

0 references

0 references

2

Frank L Greenway

1 reference

24 August 2017

Sonja K Billes

1

1 reference

PubMed ID

21689063

24 August 2017

language of work or name

English

0 references

publication date

21 June 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

11

1 reference

24 August 2017

1813-1826

1 reference

WHO recognition of the global obesity epidemic

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Central nervous system control of food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Psychotropic drugs in the treatment of obesity: what promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Social reactions to Valium and Prozac: a cultural lag perspective of drug diffusion and adoption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Congenital leptin deficiency is associated with severe early-onset obesity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Weight-reducing effects of the plasma protein encoded by the obese gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Anatomy and regulation of the central melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Antihypertensive medications and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Effects of long-term therapy with naltrexone on body weight in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Bioelectrical impedance vs. four-compartment model to assess body fat change in overweight adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Food craving, dietary restraint and mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Food cravings in young and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

The psychology of food craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Obesity prevalence in the United States--up, down, or sideways?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

The epidemiology of obesity: the size of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

21 January 2018

The Epidemic of Obesity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.591382

10.1517/14656566.2011.591382

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21689063